-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-06-05
GRI:NSD-GRI Bio Inc. (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 1.43Change
-0.02 (-1.38)%Market Cap
N/AVolume
0.06MAnalyst Target
N/A
N/A
Verdict
Values as of: 2025-06-05
COMMON STOCK | Biotechnology |
Last Closing
USD 1.43Change
-0.02 (-1.38)%Market Cap
N/AVolume
0.06MAnalyst Target
N/AN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
-2.03 (-0.46%) |
USD 128.84B |
REGN | Regeneron Pharmaceuticals Inc |
-1.86 (-0.38%) |
USD 65.38B |
ARGX | argenx NV ADR |
+7.09 (+1.24%) |
USD 34.54B |
ALNY | Alnylam Pharmaceuticals Inc |
+2.69 (+0.88%) |
USD 32.75B |
ONC | BeiGene, Ltd. |
-1.27 (-0.49%) |
USD 27.70B |
RPRX | Royalty Pharma Plc |
+0.31 (+0.93%) |
USD 18.35B |
SMMT | Summit Therapeutics PLC |
+0.17 (+0.87%) |
USD 13.53B |
INSM | Insmed Inc |
-0.95 (-1.29%) |
USD 11.84B |
INCY | Incyte Corporation |
-0.18 (-0.27%) |
USD 11.42B |
BMRN | Biomarin Pharmaceutical Inc |
-0.84 (-1.50%) |
USD 11.29B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
UKPH:XETRA | iShares UK Property UCITS.. | 3.23 % | 0.00 % |
-0.02 (-0.40%) |
N/A |
IUKP:LSE | iShares UK Property UCITS | 3.07 % | 0.00 % |
-1.25 (-0.40%) |
USD 0.51B |
IUKP:SW | iShares UK Property UCITS.. | 3.03 % | 0.00 % |
N/A |
USD 0.51B |
UKRE:LSE | iShares MSCI Target UK Re.. | 0.00 % | 0.00 % |
-2.20 (-0.40%) |
USD 0.10B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -89.85% | 2% | F | 1% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -89.85% | 2% | F | 1% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -97.70% | 3% | F | 2% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -97.70% | 3% | F | 2% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -100.00% | N/A | F | N/A | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -100.00% | N/A | F | N/A | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -45.26% | 4% | F | 2% | F | ||
Dividend Return | -45.26% | 4% | F | 2% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 48.42% | 64% | D | 37% | F | ||
Risk Adjusted Return | -93.47% | 10% | F | 5% | F | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This stock has shown below median earnings growth in the previous 5 years compared to its sector